Siplizumab
As of the edition of 20 October 2026, Siplizumab is an antibody: in active development; acts on CD2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 24, 10 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Pregnancy and women's health; Urinary and reproductive; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Siplizumab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD2 | T-cell surface antigen CD2 | P06729 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 4 | 2 | 3 |
| Phase 2 | 15 | 5 | 3 | 7 |
| All trials | 24 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 1997 to now |
| ITB-Med | Lead sponsor of trials | 2021 to now |
| Nefro Avillion Clinical | Lead sponsor of trials | 2026 to now |